Sep 26, 2018
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Sep 25, 2018
Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer
Sep 25, 2018
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial
Aug 01, 2018
Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
Jul 31, 2018
Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer
Jul 12, 2018
Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial
Jun 26, 2018
Aldeyra Therapeutics Announces Development Programs at 2018 Research Day
Jun 25, 2018
Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes
Jun 20, 2018
Aldeyra Therapeutics Announces 2018 Research Day
May 15, 2018
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
May 10, 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
May 09, 2018
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
May 01, 2018
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
Apr 24, 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
Mar 29, 2018
Aldeyra Therapeutics Announces Year End 2017 Financial Results
Mar 22, 2018
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results
Feb 27, 2018
Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
Feb 21, 2018
Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Jan 30, 2018
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
Nov 29, 2017
Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting